Clin2
NCT06745583Possibly a fitRecruiting

Testing an oral drug for brain inflammation in Alzheimer's

Mild, Moderate, or Severe Alzheimer's Disease

Part of Blood & lymphatic, Brain & nervous system, Cancer, Immune system & allergy, Mental health clinical trials.

This study tests an experimental oral medication (EI-1071) to see if it can reduce brain inflammation in people with Alzheimer's disease. The goal is to learn if it is safe and might help slow cognitive decline.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
15 people
Ages
50 years to 85 years
Study type
Interventional

Who can take part

  • You have a diagnosis of mild to severe Alzheimer's disease.
  • You are not taking any Alzheimer's medication that has changed in the last 8 weeks.
  • Your weight is less than 330 pounds (150 kg).
  • You do not have an active infection like tuberculosis, hepatitis B or C, or HIV.
  • You are willing to use birth control if you or your partner could become pregnant.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT05413655Recruiting· Phase 2
Oral drug for mild Alzheimer’s disease symptoms

This Phase 2 trial tests an oral medicine (EX039) to see if it can help people with mild Alzheimer’s disease. It focuses on slowing or improving thinking and memory problems over time.

Taipei
NCT07252440Recruiting· Phase 2
Testing an oral drug for early Alzheimer's disease

This study tests an oral tablet (TTYP01) for people with early Alzheimer's disease. It aims to see if the drug can slow memory loss. You must have a study partner who can support you throughout the trial.

Chongqing, Chongqing Municipality
NCT07781657Not yet recruiting· Phase 2
Testing an experimental drug for early Alzheimer's disease

This study tests an experimental medication called RO7568282 to see if it can slow down memory decline in people with early Alzheimer's disease. If you have early memory problems and a confirmed Alzheimer's-related brain change, you may be able to join.

NCT06885567Not yet recruiting· Phase 2
Testing BEY2153 for Early Alzheimer's Disease

This study tests an investigational drug called BEY2153 for people with early Alzheimer's disease (mild cognitive impairment or mild dementia). The goal is to see if it is safe and slows down memory decline.

Seoul
NCT06619613Recruiting· Phase 1
Study of CM383 for early Alzheimer's disease

This trial tests a new drug called CM383 in people with mild cognitive impairment or mild Alzheimer's disease. The goal is to see if it can help slow down memory loss.

Hefei
NCT07058688Recruiting· Phase 2
Testing a new drug for Alzheimer's (NTRX-07)

This study tests an experimental drug for Alzheimer's called NTRX-07. It aims to see if it can slow memory decline for people with mild to moderate Alzheimer's.

Brno

Hear when a new Mild, Moderate, or Severe Alzheimer's Disease trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.